Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales, general and administrative

Merger-related expenses

Change in fair value of contingent consideration

Amortization of acquired intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pacific Biosciences of California

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacific Biosciences sees strong Revio demand driving revenue growth

PACB reported a revenue decrease in Q4 2022 but saw strong customer interest in the Revio system, driving revenue growth expectations for 2023. The company is strategically focused on Revio adoption, Onso's performance, and managing market challenges. Opportunities exist in scaling manufacturing capacity, expanding customer reach, and leveraging high demand for Revio and Onso.

PacBio surpasses revenue expectations with strong Revio demand

PacBio's Q1 2023 performance exceeded expectations with record revenue and strong Revio demand, setting up growth opportunities.
While facing challenges in gross margin and operating expenses, PacBio's innovative approach and broad market appeal position it well for the future.
With a focus on margin expansion, consumables growth, and balancing product demand, PacBio aims for sustained profitability and market leadership.
The successful Revio launch and strong China business highlight PacBio's potential for long-term growth and market impact.

PacBio reports record Q2 revenue, eyes market gains and gross margin improvements

PacBio's Q2 performance marked by record revenue, strategic acquisitions, and strong guidance update for 2023 growth.
Focus on Revio system adoption, consumables pull-through, and backlog reduction positions the company for sustained success.
Challenges include market competition, sustaining growth post-upgrade cycle, and addressing validation issues for new products.
Opportunities lie in market shifts towards long reads, improving gross margins through product mix changes, and expanding market access.

PacBio reports record Q3 revenue growth and strategic advancements

PacBio delivered robust performance in Q3, achieving record revenue and strong growth, driven by increased demand for Revio systems and consumables.
While facing challenges such as budget constraints and macroeconomic uncertainties, PacBio's strategic strengths lie in product innovation, market expansion, and financial stability.
Opportunities abound in collaborations, technology enhancements, and market growth, positioning PacBio for continued success and leadership in the genomics industry.
With a positive outlook for future revenue growth, PacBio remains focused on driving innovation, expanding its customer base, and navigating market challenges.

Pacific Biosciences reports robust 2023 performance and eyes growth

PACB had a strong 2023 with revenue growth and successful Revio adoption, despite challenges in China impacting placements.
New kits, software updates, and positive customer feedback on platforms indicate market acceptance and drive customer enthusiasm.
Strategic priorities for 2024 focus on expansion, technology development, and revenue growth, with opportunities in clinical markets and alternative business models.

Pacific Biosciences reports Q2 revenue below expectations, focuses on growth

Pacific Biosciences of California reported Q2 revenue below expectations but showed strength in consumable revenue growth. The company is focused on reducing expenses, improving cash burn, and driving instrument placements. Despite challenges, there are opportunities for growth through attractive deals and positive outlook for consumables.
The company's performance in Q2 reflects ongoing efforts to improve margins and drive revenue growth. Challenges in revenue expectations and headwinds are being addressed through cost reductions and strategic initiatives. Pacific Biosciences remains confident in its progress and future prospects.
With a focus on cost reduction, revenue improvement, and strategic priorities, Pacific Biosciences aims to achieve cash flow positivity by 2026. The company's strengths lie in consumable revenue growth, successful marketing events, and confidence in its product pipeline. Challenges in revenue and cash flow are being managed with opportunities for growth through instrument placements and deals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

PacBio (PACB) witnesses strong revenue growth in the third quarter, partly aided by customers' continued product transition to the Revio system.

PacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue View

Building on the MAS-Seq Concatenation Method, These Three New Kits can Significantly Increase Throughput in RNA Applications MENLO PARK, Calif. , Oct. 31, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it has begun taking orders for its groundbreaking Kinnex RNA kits, which increase throughput for full-length RNA, single-cell RNA, and 16S rRNA sequencing on PacBio's long-read sequencing systems to enable large-scale studies at a resolution difficult to attain with short-read RNA sequencing.

PacBio Announces Kinnex RNA Kits, Further Scaling HiFi Sequencing in Full-Length RNA, Single-Cell RNA and 16S rRNA Applications

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2023 Earnings Conference Call October 30, 2023 4:30 PM ET Company Participants Todd Friedman - Senior Director, Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Kyle Mikson - Canaccord Jack Meehan - Nephron Research Eve Burstein - Bernstein Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen John Sourbeer - UBS Sung Ji Nam - Scotiabank Luke Sergott - Barclays Operator Good afternoon, everyone, and welcome to the PacBio Third Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.

Pacific Biosciences of California, Inc. (PACB) Q3 2023 Earnings Call Transcript

MENLO PARK, Calif. , Oct. 30, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023.

PacBio Announces Third Quarter 2023 Financial Results

Two of Cathie Wood's Ark Invest ETFs loaded up on shares of Pacific Biosciences of California (PacBio). PacBio is an innovative disruptor in the genetic sequencing market.

Cathie Wood Just Added $5 Million of This Stock After It Had a Steep Pullback. Is It a No-Brainer Buy?

PacBio's (PACB) latest software pipeline is likely to provide standardization to HiFi WGS analysis.

PacBio's (PACB) New Offering to Boost WGS Data Analysis

Former CFO of Moderna, Amgen, and 3M Brings Decades of Relevant Experience to the PacBio Board MENLO PARK, Calif. , Oct. 16, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Meline to its Board of Directors, effective October 13, 2023.

PacBio Announces Appointment of David Meline to Board of Directors

MENLO PARK, Calif. , Oct. 12, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2023 financial results on Monday, October 30, 2023, at 4:30 pm Eastern Time.

PacBio to Report Third Quarter 2023 Financial Results on October 30, 2023

PacBio WGS Variant Pipeline Will Bring Standardization to PacBio HiFi Data Analysis MENLO PARK, Calif. , Oct. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of PacBio WGS Variant Pipeline – a complete, standardized computational method for HiFi whole genome sequencing (WGS) data analysis.

PacBio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

PacBio's (PACB) product development activities raise optimism about the stock.

Three Reasons to Add PacBio (PACB) Stock to Your Portfolio

Pacific Biosciences (PACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Strength Seen in Pacific Biosciences (PACB): Can Its 8.9% Jump Turn into More Strength?

Pacific Biosciences of California Inc (PacBio), the California-based developer of high-quality and highly accurate sequencing solutions, has launched of a new program called PacBio Capital to expand access to PacBio's highly accurate sequencing systems by providing customers with flexible financing options. The moves makes its advanced sequencing systems more accessible to researchers and laboratories by offering flexible leasing options with competitive rates.

PacBio shares jump as launch of capital program boosts sequencing access

New Program Expands Access to PacBio's Highly Accurate Sequencing Systems by Providing Flexible Financing   MENLO PARK, Calif. , Sept. 12, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PacBio Capital, a program that offers customers the ability to lease PacBio sequencing systems – Revio, Onso and Sequel IIe – easily and cost-effectively.

PacBio Announces PacBio Capital

Pacific Biosciences has a leading position within the fast-growing long-read DNA sequencer market. Moreover, it is expanding its high-accuracy long-read portfolio to grab more market share from Illumina. My DCF model indicates significant upside potential. A sensitivity analysis shows that downside potential seems also limited. The complementary credit analysis I performed rules out any large need of capital increase for liquidity reason.

Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Market

Beam Therapeutics

Spotify

Cathie Wood recently bought shares of Beam Therapeutics, a clinical-stage drugmaker testing out a new way to edit troublesome genes. Ark Invest also acquired shares of Pacific Biosciences of California, a genetic sequencing company, multiple times this week.

Cathie Wood's Buying These 3 Stocks Hand Over Fist

Hamilton, Integra, Revvity, and Tecan Join PacBio Compatible to Offer Verified Automated Library Prep Workflows for Whole Genome Sequencing MENLO PARK, Calif. , Sept. 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that automation providers Hamilton, Integra, Revvity and Tecan have created fully automated protocols to prepare samples for sequencing on Revio and Sequel II and IIe systems.

PacBio Announces Collaboration with Leading Library Preparation Automation Partners

Here's Why You Should Retain PacBio (PACB) Stock for Now

PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Revio system to explore novel variants.

PacBio (PACB) Inks Research Collaboration for Genome Sequencing

GeneDx Holdings Corp

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms  MENLO PARK, Calif. and STAMFORD, Conn.

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

MENLO PARK, Calif. , Aug. 4, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that PacBio's Compensation Committee of the  Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock and restricted stock units ("RSUs") covering 184,700 shares of PacBio common stock to fourteen non-executive employees, in connection with their commencement of employment as part PacBio's acquisition of Apton Biosystems, Inc., under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan"), with such grants effective on August 2, 2023 (the "Effective Date").

PacBio Reports Equity Incentive Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4)

PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.

PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Todd Friedman - Director, Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Kyle Mikson - Canaccord Jack Meehan - Nephron Research Daniel Brennan - TD Cowen Sung Ji Nam - Scotiabank Luke Sergott - Barclays Rachel Vatnsdal - JP Morgan Tejas Savant - Morgan Stanley Ross Osborn - Cantor Fitzgerald Operator Hello and welcome to the PacBio Second Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode.

Pacific Biosciences of California, Inc. (PACB) Q2 2023 Earnings Call Transcript

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.34 per share a year ago.

Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates

MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2023.

PacBio Announces Second Quarter 2023 Financial Results

PacBio will Combine Apton's Proprietary Sequencing Technology With its Highly Accurate Sequencing by Binding Chemistry to Develop a High-Throughput Sequencer Designed to Deliver Billions of Reads per Flow Cell MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into an agreement to acquire Apton Biosystems, Inc (Apton), a Bay-Area-based company developing a high throughput short-read sequencer using state-of-the-art optics and image processing, paired with novel clustering and chemistry, that is designed to enable the sequencing of billions of clusters of DNA on one flow cell.

News for Pacific Biosciences of California Stock (PACB)